Morphine HydrochlorideMORPHINE JUNO
Relief of moderate to severe pain not responsive to non-opioid analgesics, symptomatic relief of severe and intractable pains in terminal cancer patients, and as a pre-operative medication and analgesic adjunct in general anaesthesia.
Decisions on record
- Meeting Jul 2024 Recommended Severe pain, cancer pain, severe disabling pain
- Meeting Mar 2019 Recommended Chronic breathlessness
- Meeting Mar 2016 Recommended Pain
Access path
- TGA registered · MORPHINE JUNO
TGA label equal than the PBS population
- Mar 2016Recommended
vs morphine sulfate and morphine tartrate
- PBS listing · Unrestricted
From the public summary
5.1 The PBAC recommended listing the 10 mg/mL, 20 mg/mL, 50 mg/5 mL, and 100 mg/5 mL strengths of morphine (as morphine hydrochloride) under the same circumstances as per the current listings for morphine (as morphine sulfate and morphine tartrate).PSD · Mar 2016
5.2 The PBAC noted that the TGA considered the new forms of morphine injection (as morphine hydrochloride) as bioequivalent to the currently listed forms of morphine injection (as morphine sulfate and morphine tartrate), and noted that the new listing would trigger a 16% statutory price reduction to the drug morphine with manner of administration injection.PSD · Mar 2016
4.3 As a minor submission, there was no economic comparison presented. 1PSD · Mar 2016
4.4 The submission assumed the listing of morphine (as morphine hydrochloride) to be cost neutral as it was calculated on a “pricing per mg” basis as the currently listed forms of morphine (as morphine sulfate) as per the following: 10 mg/mL - same price as the morphine sulfate 10 mg/mL 20 mg/mL - same price as the morphine sulfate 15 mg/mL 50 mg/mL - same price as the morphine sulfate 30 mg/mL 100 mg/mL - same price as the morphine sulfate 30 mg/mLPSD · Mar 2016
Cost-effectiveness
Minor submission with no economic comparison; cost-neutral on a price per mg basis.
Decision context
PopulationPatients requiring relief of moderate to severe pain not responsive to non-opioid analgesics, severe and intractable pain in terminal cancer patients, and perioperative analgesia.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2016 | Recommended | morphine sulfate and morphine tartrate | — | Cost-minimisation · Cost-minimisation |
Consumer voice
No consumer comments were received for this item.
The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD
Similar precedents
Regulatory · TGA
Label equal than PBS population — PBAC indication matches TGA label across all three domains: non-opioid-refractory moderate-severe pain, terminal cancer pain, and perioperative use.